Despite a significant downturn in its stock price, Novo Nordisk continues to attract investment from major players. The Norwegian government’s investment fund, Folketrygdfondet, recently purchased an additional 1 billion Norwegian kroner (approximately $92.8 million USD as of February 17, 2026) worth of shares in the Danish pharmaceutical giant, signaling continued confidence in the company’s long-term prospects. This move comes as Novo Nordisk faces increased competition in the rapidly evolving weight-loss drug market and navigates a challenging geopolitical landscape.
The investment underscores a belief in Novo Nordisk’s underlying strength, even after the company’s market value plummeted from over 4.5 trillion Danish kroner in the summer of 2024 to under 1.4 trillion Danish kroner currently, according to Bloomberg data. Folketrygdfondet’s decision to increase its stake, despite Novo Nordisk being the largest detractor from its portfolio last year – with a 46% decline impacting overall returns by 1.89 percentage points – highlights a strategic long-term view. As of the end of 2025, the fund held Novo Nordisk shares valued at 5.2 billion Norwegian kroner.
Novo Nordisk’s Market Challenges
Novo Nordisk’s initial success was built on its dominance in the insulin market for diabetes treatment, but the company has expanded significantly into the burgeoning market for weight-loss medications. Sales within this segment surged from 6 billion Danish kroner in 2019 to 82 billion Danish kroner in 2025, as reported by the company. However, this growth has attracted fierce competition, particularly from U.S.-based Eli Lilly, whose stock has remained robust even as Novo Nordisk’s has faltered.
“When you compare with Eli Lilly, which is a quite comparable company, the development is very different in the two,” said Kjetil Houg, CEO of Folketrygdfondet, in an interview. He noted that some analysts believe Eli Lilly possesses a stronger product portfolio. The rise of generic competitors targeting Novo Nordisk’s products has added pressure. Houg also pointed to geopolitical factors, suggesting that Novo Nordisk’s status as a Danish company exporting heavily to the U.S. May be contributing to the challenges it faces.
Folketrygdfondet’s Portfolio and Strategy
Folketrygdfondet, which manages 429 billion Norwegian kroner in stocks and bonds, delivered a total return of 48 billion Norwegian kroner in 2025. The fund primarily invests in the Nordic region, with approximately 12% of its holdings concentrated in the Oslo Stock Exchange. We see distinct from Norway’s larger sovereign wealth fund, Statens pensjonsfond utland (the Oil Fund), which invests globally.
The fund’s confidence in Novo Nordisk is not isolated. Folketrygdfondet also made a significant investment in Akers AI, holding values worth 6.7 billion kroner. Houg emphasized the fund’s belief in Novo Nordisk’s fundamental strengths, stating, “We believe that Novo has fantastic products and is a very good company. They have had a lot of adversity now in several areas and have also changed leadership. But fundamentally, it is still a strong company.”
Looking Ahead
The situation highlights the volatility inherent in the pharmaceutical market, particularly in rapidly growing sectors like weight-loss drugs. Novo Nordisk’s ability to navigate increased competition, address concerns about generic alternatives, and mitigate potential geopolitical headwinds will be crucial for its future success. Folketrygdfondet’s continued investment suggests a belief that the company is well-positioned to overcome these challenges and regain its footing. The coming quarters will be critical in determining whether this confidence is justified.
What are your thoughts on the future of Novo Nordisk? Share your insights in the comments below.
Disclaimer: This article provides informational content only and should not be considered financial or medical advice. Consult with a qualified professional for personalized guidance.
